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Parvalbumin-Neurons of the
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Nucleus Receive a Glycinergic Input:
A Gene-Microarray Study
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Anatomy and Program in Neuroscience, Department of Medicine, University of Fribourg, Fribourg, Switzerland
The ventrolateral hypothalamic parvafox (formerly called PV1-Foxb1) nucleus is an
anatomical entity of recent discovery and unknown function. With a view to gaining an
insight into its putative functional role(s), we conducted a gene-microarray analysis and,
armed with the forthcoming data, controlled the results with the Allen databases and
the murine BrainStars (B∗) database. The parvafox nucleus was specifically sampled
by laser-capture microdissection and the transcriptome was subjected to a microarray
analysis on Affymetrix chips. Eighty-two relevant genes were found to be potentially more
expressed in this brain region than in either the cerebral cortex or the hippocampus.When
the expression patterns of these genes were counterchecked in the Allen-Database of
in-situ hybridizations and in the B∗-microarray database, their localization in the parvafox
region was confirmed for thirteen. For nine novel genes, which are particularly interesting
because of their possible involvement in neuromodulation, the expression was verified by
quantitative real time-PCR. Of particular functional importance may be the occurrence
of glycine receptors, the presence of which indicates that the activity of the parvafox
nucleus is under ascending inhibitory control.
Keywords: parvalbumin, laser capture microdissection, glycine receptor α2, Allen Brain Atlas Database of in-situ
hybridizations (ABA-ISH), BrainStars (B∗) microarrays, PV1-Foxb1, parvafox, GlyT2-EGFP
INTRODUCTION
The parvafox nucleus (formerly known as PV1-Foxb1 nucleus) has been identified and described
as a bilateral chord of parvalbumin (Parv)-positive neurons in the murine ventrolateral tuberal
hypothalamus (Celio, 1990; Mészár et al., 2012; Bilella et al., 2014). It is sandwiched in the
horizontal plane between the optic tract and the fornix, and in mice it extends for a total length
of about 1mm. Parv-positive cells of the parvafox nucleus are immunoreactive for glutamate
Abbreviations: 3V, third ventricle; ABA, Allen Brain Atlas; ABA-ISH, Allen Brain Atlas of in-situ hybridizations; BMA,
basomedial amygdalar nucleus; Cx, cortex; DMH, dorsomedial hypothalamic nucleus; f, fornix; fc, fold-change; Gad1,
glutamate decarboxylase 1; Glra1, glycine receptor, alpha 1 subunit (gene); Glra2, glycine receptor, alpha 2 subunit (gene);
Glra3, glycine receptor, alpha 3 subunit (gene); Glyrα2; glycine receptor, alpha 2 subunit (protein); Glyrα3, glycine receptor,
alpha 3 subunit (protein); hp, hippocampus; ic, internal capsule; ISH, in-situ hybridization; LHA, lateral hypothalamic area;
MEA, medial amygdalar nucleus; mt, mammillothalamic tract; ns, nigrostriatal bundle; opt, optic tract; Parv, parvalbumin
(protein); Pvalb, parvalbumin (gene); Slc17a6, solute carrier family 17 member 6; Slc17a7, solute carrier family 17 member 7;
STh, subthalamic nucleus; TH, thalamus; VMH, ventromedial hypothalamic nucleus; ZI, Zona incerta.
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(Mészár et al., 2012) and express the gene Slc17a6 encoding
the vesicular glutamate transporter 2 (Vglut2) (Girard et al.,
2011). Hence, unlike the usual GABA-phenotype (Celio, 1986),
the Parv-positive neurons of the parvafox nucleus utilize the
excitatory neurotransmitter glutamate.
The efferent connections of the Parv-positive sub-population
of neurons in the parvafox nucleus are almost exclusively directed
toward a small cylindrical zone lying ventral to the aqueduct
in the periaqueductal gray matter (PAG) (Celio et al., 2013).
The targets of the Foxb1-cell subpopulation of the parvafox
nucleus are likewise located in and around the PAG, but occur
also in a few other cerebral sites (Bilella et al., 2016). The
inputs to the parvafox nucleus, as studied by trans-synaptic
retrograde transport of rabies-virus, derive from a wide variety
of brain sites, including orbitofrontal cortex, piriform cortex,
olfactory tubercle, nucleus accumbens, caudoputamen, globus
pallidus, diagonal band nucleus (NDB), substantia innominata
(SI), bed nuclei of the stria terminalis (BST), anterior amygdalar
area, central and medial amygdalar nucleus, thalamus [(lateral
dorsal nucleus of the thalamus (LD), mediodorsal nucleus
of the thalamus (MD)], midbrain (PAG, ventral tegmental
area, midbrain reticular nucleus), pons, medulla oblongata
[Gigantocellular reticular nucleus (GRN), Intermediate reticular
nucleus (IRN)] (manuscript in preparation). The functions of this
lateral hypothalamic parvafox nucleus are as yet unknown.
The identification of genes that are enriched in the neurons
of the parvafox nucleus could reveal the presence of components
that might provide an insight into the role(s) of this brain entity.
A genome-wide molecular characterization of the parvafox
nucleus has been already undertaken by a screening of the Allen
Brain Atlas Database of in-situ hybridizations (ABA-ISH) (Girard
et al., 2011). This former study disclosed 76 genes as being
potentially co-expressed with Parv in the neurons of the parvafox
nucleus, a large number of them being common to all Parv-
positive neurons in the brain (e.g., those that are implicated in the
regulation of potassium–channels). Somewhat surprisingly, only
a few of the genes that encode neuromodulators or their receptors
were found to be expressed in the parvafox nucleus.
With a view to complementing these early data and to
disclosing genes encoding neuropeptides, neurotransmitters
and their receptors, the entire transcriptome of the parvafox
nucleus was subjected to a gene-microarray of laser-capture
microdissected murine tissue. Armed with these data, we
scrutinized the Allen Database of in-situ hybridizations (ABA-
ISH; http://www.brain-map.org/) (Lein et al., 2007) and the
BrainStars (B∗)-Database of gene arrays (Kasukawa et al., 2011;
http://brainstars.org/). The most significant outcome of this
gene-array investigation was the discovery of glycine-receptor
alpha subunits expressed in the parvafox nucleus.
MATERIALS AND METHODS
Mice
Adult C57BL/6 and GlyT2-EGFP mice of both sexes were used
in this study. GlyT2-EGFP mice were a kind gift of Prof. Hanns
Ulrich Zeilhofer (University of Zürich, Neuropharmacology). All
animal experiments were carried out in accordance with the
institutional guidelines of the University of Fribourg and with
the permission of the Swiss federal and cantonal committee on
animal experimentation.
Gene-Microarray Analysis
Six C57BL/6 mice were killed by cervical dislocation. The brains
were rapidly removed, mounted on cork platforms in OCT
(Sakura Tissue-Tek), and frozen on pulverized dry ice. Prior
to sectioning in a cryostat, the samples were stored at −80◦C.
Starting from the ventral surface, the brains were cut into 16-µm-
thick horizontal sections at −18◦C until the fornix was reached.
At this point, the sections were respectively mounted in an
alternating manner on MMI-membranes (Molecular Machines
& Industries, Glattbrugg, Switzerland) and Superfrost-Plus glass
slides (Menzel-Gläser, Braunschweig, Germany). The MMI-
mounted sections were chemically fixed for 5 min in 100%
ethanol at −18◦C, air dried for 1 h in the cryostat chamber,
likewise at −18◦C and stored at −80◦C for various periods of
time until the time of laser-beam-aided microdissection. The
Superfrost-Plus-mounted sections were chemically fixed for 10
min at ambient temperature in 4% paraformaldehyde diluted in
phosphate-buffered saline (0.1M, pH 7.3). These sections were
incubated overnight at 4◦C with the horseradish-peroxidase-
conjugated lectin Vicia villosa (EY Laboratories, San Mateo,
California, USA) at a concentration of 20 µg/ml in 0.1 M Tris-
buffered saline containing 0.1 mM MnCl2, 0.1 mM CaCl2, 0.1
mM MgCl2 and 0.1% Triton-X. The presence of the lectin
staining was revealed after treatment with diaminobenzidine /
hydrogen peroxide. Lectins such as Vicia villosa are markers
of the perineuronal nets (Celio and Blümcke, 1994), which
are abundant around the Parv-immunopositive neurons of the
rodent parvafox nucleus (Mészár et al., 2012). The pattern of
lectin staining on the Superfrost-Plus-mounted sections aided
the localization of the parvafox nucleus on the adjacent, MMI-
membrane-mounted ones.
Using vessels as landmarks, the corresponding parvafox
region on the MMI-membranes was excised using the CellCut-
Plus laser microdissection apparatus (MMI, Glattbrugg,
Switzerland) of the Cellular Imaging Facility (CIF) at the
University of Lausanne. The previously drawn trajectory was
automatically excised using the precisely focused UV-laser beam.
The dissected tissue samples were collected in special tubes
bearing an adhesive surface on the interior of the cap (MMI,
Glattbrugg, Switzerland). Finally, 350 µl of lysis buffer [Buffer
RLT (Qiagen), supplemented with 1:100 β-mercaptoethanol]
was added to each tube and the samples were immediately
frozen at −80◦C. The same protocol was used to extract tissue
from regions encompassing the cerebral cortex (piriform and
entorhinal cortex) and the hippocampus (CA2–CA3 area). These
regions were arbitrarily chosen as a basis for comparison in so
far they contain GABAergic, Parv-positive interneurons. Hence,
from each murine brain, three regions were excised: the parvafox
nucleus, the cortex and the hippocampus.
The entire RNA-pool of the microdissected cryosections was
purified using the RNAeasy Plus Micro Kit (Qiagen, Hilden,
Germany). The quantity and the quality of the RNA-extracts were
respectively monitored in a NanoDrop 2000 spectrophotometer
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(Thermo Scientific, Wilmington, DE, USA) and an Agilent 2100
bioanalyzer (Agilent Technologies, Palo Alto, California, USA).
For the final gene-array we used the tissue of two mice (m355
and m511) from which the RNA-extract was best preserved
and at the highest concentrations. The samples of these animals
were analyzed separately so as to furnish independent replicates.
The RNA-samples were stored at −80◦C until the time of
amplification using the NuGEN Ovation R© Pico WTA System
V2 (NuGEN Technologies, San Carlos, California, USA) as
previously described (Szabolcsi and Celio, 2015). The whole-
transcript amplification, the labeling process and the gene-
chip hybridization on an Affymetrix Mouse Gene 2.0 ST Array
(Affymetrix, Santa Clara, California, USA) were performed in
the Genomic Technologies Facility (GTF) at the University of
Lausanne (UNIL). Excel spreadsheets containing the extracted
data were produced alongside the original files that were
generated using the Affymetrix GeneChip R© System.
Quantitative Real-Time-PCR
Verification of the results of the gene microarray was performed
by quantitative real-time-PCR (qRT-PCR). The same cDNA
samples as used for the microarray analyses were subjected
to SYBR qRT-PCR. Nine particularly interesting genes found
enriched in the parvafox nucleus of the mice in our microarray
study (Cbln1, Drd2, Ephb1, Foxb1, Glra1, Glra2, Glra3, Npb,
Npsr1) were selected for the assay. Actin beta (Actb) was chosen
as internal normalization gene. The qRT-PCR reactions were
performed using Rotor-Gene Strip Tubes (Starlab Switzerland,
Muri, Switzerland) in FastStart Essential DNA Green Master
(Roche, Rotkreuz, Switzerland) containing 0.5 µM gene-specific
primers and 5 ng cDNA/tube. The sequence of the primer
pairs is listed in Supplementary Table 3. Assays were performed
with a Rotor-Gene 6000 by Corbett Research (QIAGEN, Basel,
Switzerland). The cycling program initiated with a 10 min hold
at 95◦C, and the cycles consisted of 20 s hold at 95◦C, 20 s hold at
60◦C, 20 s hold at 72◦C, with 40 repeats. All samples were run in
triplicates and CT values were averaged for final quantification.
Immunohistochemistry
Three C57BL/6 and two GlyT2-EGFPmouse brains were fixed by
perfusion through the heart of 0.9% NaCl solution followed by
cold 4% paraformaldehyde (PFA) diluted in phosphate-buffered
saline (0.1 M, pH 7.3) and post-fixed overnight in the same
buffer. The brains were transferred to cryoprotectant solution
(30% saccharose in Tris-buffered saline 0.1 M, pH 7.3) and cut
into 40 µm-thick coronal sections with a freezing microtome
(Frigomobil, Reichert-Jung, Vienna, Austria). C57BL/6 sections
were incubated for various length of time (1 to 3 days) with
Glyrα2 antibody (Santa Cruz; Dallas, TX, USA; sc 20133) diluted
1:250 to 1:1000 (together with the monoclonal Parv antibody
235 (1: 1000; Swant Inc., Marly, Switzerland). The specificity
of the Glyrα2 antibody was tested on 40 µm-thick sections of
the prefrontal cortex derived from adult Glra2-KO mice, a kind
gift of Prof. Bert Brône’s lab (Morelli et al., 2016) (data not
shown). GlyT2-EGFP sections were incubated overnight with
monoclonal anti-GFP (1:1000, Molecular Probes, Thermo Fisher
Scientific, Reinach, Switzerland) and polyclonal Parv antibody
(PV-25, 1:1000, Swant Inc., Marly, Switzerland). Glyrα2-
immunolabeling was revealed with the fluorescent avidin-biotin
method (Vector labs), whereas GFP- and Parv-immunolabeling
was detected with fluorophore conjugated secondary antibodies
(Jackson Immunochemicals). Images were taken by a Leica
epifluorescence microscope (DM6000B) and a Leica TCS SP5
confocal laser microscope. Image analyses and three-dimensional
reconstructions were performed with the Imaris 8.3 software
module (Bitplane, Zürich, Switzerland).
Immunoblot
To obtain hypothalamic protein extracts, two C57BL/6 mice
were subjected to cervical dislocation, followed by removal of
the brains and manual excision of the hypothalamic, cortical
and hippocampal regions. Total protein content of the excised
tissue was extracted by ultrasonication in Tris-EDTA solution.
Protein extracts were subjected to 10% SDS-gel-electrophoresis
(50 µg protein) followed by transfer on nitrocellulose paper and
immunoblot using an antibody directed against Glyrα2 (Santa
Cruz, sc20133) diluted 1:500. The bound antibody was revealed
with an HRP-labeled secondary antibody and the reaction
amplified by chemiluminescence.
Informatics
Data were pre-processed and normalized using the robust multi-
array average (RMA) approach and the software “Expression
Console” provided by Affymetrix (version 1.2.1.20). The data
were evaluated using the programming language R (version
2.14.2) and Partek R© Genomics SuiteTM software (Partek Inc., St.
Louis, Missouri, USA). Gene lists were prepared by the Genomic
Technologies Facility of Lausanne using the Bioconductor
package limma in R. NCBI Gene Expression Omnibus (GEO)
database accession number of the gene microarray data is
GSE92955.
The data gleaned from our gene-microarray analysis were
compared to those derived by mining the B∗-database and the
Allenminer screening (v1.5) (Davis and Eddy, 2009), in order to
retrieve the three-dimensional expression files that were prepared
from the ABA-ISH database (Lein et al., 2007) in a former study
(Girard et al., 2011).
Mining of the BrainStars (B∗) Database
BrainStars (B∗) (http://brainstars.org/) is a quantitative
expression database of the adult murine brain (Kasukawa
et al., 2011); it contains a genome-wide expression-profile of 51
regions. We exploited this publicly available expression-profile
database to check our own gene-microarray analysis. Data
appertaining to the lateral hypothalamus were compared with
those derived from the cerebral cortex and the hippocampus.
MetaCore Software Analysis
Further analysis of the data was performed using MetaCore
(Thomson Reuters, New York, NY, USA), a data mining
and pathway-analysis software facility, which is commonly
implemented for a functional analysis of gene-microarray
findings. The known and putative functions of specific genes, as
well as their involvement in biological and molecular processes,
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TABLE 1 | List of the 82 genes that were enriched in the parvafox nucleus relative to the expression levels in the cortex and/or the hippocampus in our
own gene-microarray analysis, and their localization counter-checked in the ABA-ISH database.
Gene Complete name fc_m355_
nu_cx
fc_m355_
nu_hp
fc_m511_
nu_cx
fc_m511_
nu_hp
NOT
in ABA
NEG
in ABA
POS
in ABA
POS
in LH
POS in
parvafox
Adcyap1 Adenylate cyclase
activating polypeptide 1
3.92 27.23 5.00 4.81 v v
Agt Angiotensinogen 2.33 3.27 8.61 5.77 v v (glia)
Agxt2l1 Alanine-glyoxylate
aminotransferase 2-like 1
2.26 4.45 6.15 5.99 v
Ano4 Anoctamin 4 2.12 2.83 3.20 2.81 v
Apoc1 Apolipoprotein C-I 3.67 4.45 6.42 6.59 v
Baiap3 BAI1-associated protein 3 2.21 3.72 2.86 3.57 v
Capza1 Capping protein muscle
Z-line, alpha 1
2.09 2.38 3.90 2.65 v v
Cbln1 Cerebellin-1-precursor 4.51 4.17 2.68 1.74 v
Ddx5 DEAD (Asp-Glu-Ala-Asp)
box polypeptide 5
2.85 3.42 2.04 7.50 v v
Dgkk Diacylglycerol kinase
kappa
2.85 5.02 7.65 9.05 v
Drd2 Dopamine 2 receptor 2.95 2.83 −4.95 2.29 v
Ebf3 Early B cell factor 3 7.46 6.31 5.49 6.33 v
Ephb1 Ephrin b1 receptor
tyrosine kinase
2.19 2.13 1.25 2.18 v
Fam113b Family with sequence
similarity 113, member B
2.46 2.33 2.61 2.54 v
Fndc3a Fibronectin type III domain
containing 3A
2.65 2.55 2.60 2.55 v v
Foxb1 Transcription factor 3.92 4.82 1.44 1.25 v pos. in
Literature
Glra1 Glycine receptor, alpha 1
subunit
−1.91 3.86 1.90 2.62 v
Glra2 Glycine receptor, alpha 2
subunit
3.11 6.32 3.71 4.98 v v
Glra3 Glycine receptor, alpha 3
subunit
−1.19 10.41 21.52 16.93 v
Gpr139 G protein-coupled
receptor 139
6.71 5.73 2.45 2.71 v
Gpx3 Glutathione peroxidase 3 3.05 8.79 3.15 3.02 v v
Hist1h1b Histone cluster 1, H1b 5.18 4.42 2.89 24.43 v
Hmgxb4 HMG box domain
containing 4
2.09 2.27 2.27 2.23 v
Hyi Hydroxypyruvate
isomerase homolog (E.
coli)
4.04 2.87 3.98 2.18 v
Igsf1 Immunoglobulin
superfamily, member 1
2.89 2.90 14.59 13.69 v
Itih3 Inter-alpha trypsin
inhibitor, heavy chain 3
5.16 13.88 22.97 10.69 v v (glia)
Kcnab3 Potassium channel,
beta3, shaker type
2.09 2.44 1.43 −1.26 v
Lgi2 Leucine-rich g repeat 1.32 2.19 2.40 2.64 v
Lhfpl3 Lipoma HMGIC fusion
partner-like 3
2.17 5.41 2.82 2.39 v
Lhfpl5 Lipoma HMGIC fusion
partner-like 5
3.90 5.19 4.99 2.27 v
Lhx1 Lim-homobox protein 1 3.89 4.35 1.50 1.66 v
(Continued)
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TABLE 1 | Continued
Gene Complete name fc_m355_
nu_cx
fc_m355_
nu_hp
fc_m511_
nu_cx
fc_m511_
nu_hp
NOT
in ABA
NEG
in ABA
POS
in ABA
POS
in LH
POS in
parvafox
Lrrc6 Leucine rich repeat
containing 6
−1.49 1.73 2.35 2.09 v
Mpp7 Membrane protein,
palmitoylated 7
2.46 3.24 5.31 5.31 v
Mthfd2l Methylenetetrahydrofolate
dehydrogenase 2-like
3.03 3.34 5.82 4.44 v
Ndufs1 NADH dehydrogenase
Fe-S protein 1
1.04 −1.35 2.03 3.18 v
Npb Neuropeptide B 3.87 5.94 8.15 11.50 v pos. in
Literature
Npsr1 Neuropeptide S receptor 3.31 3.05 −4.50 1.20 v
Nxph4 Neurexophilin 4 6.02 14.85 4.93 2.23 v v
Penk Preproenkephalin 2.68 11.21 −5.37 4.01 v
Phyhd1 Phytanoyl-CoA
dioxygenase domain
containing 1
2.22 2.04 6.58 5.05 v
Pitx2 Paired-like homeodomain
transcription factor 2
3.06 2.83 6.61 5.78 v v
Plcb4 Phospholipase C, beta 4 2.98 4.79 2.24 2.37 v v v
Pmch Pro-melanin-
concentrating
hormone
66.57 137.92 85.36 115.62 v
Rhobtb3 Rho-related BTB domain
containing 3
2.71 3.10 2.39 2.14 v
Rmst Rhabdomyosarcoma 2
associated transcript
4.35 10.75 7.73 17.25 v
Rnf122 Ring finger protein 122 2.12 2.31 3.41 2.18 v v
Rny1 RNA, Y1 small
cytoplasmic,
Ro-associated
8.40 5.13 2.13 2.69 v
Scarna3a Small Cajal body-specific
RNA 3A
4.03 5.56 4.08 5.62 v
Serpinb1b Serine peptidase inhibitor,
clade B, member 1b
4.33 17.71 2.50 5.06 v
Sfrp5 Secreted frizzled-related
sequence protein 5
3.44 6.76 11.65 8.13 v
Slc17a6 Solute carrier family 17,
member 6
3.84 59.58 9.75 9.52 v v
Slitrk6 SLIT and NTRK-like family,
member 6
3.12 2.38 5.31 4.95 v
Snord42b Small nucleolar RNA, C/D
box 42B
3.78 13.55 4.03 3.13 v
Trav9d-3 T cell receptor alpha
variable 9D-3
3.91 6.61 18.00 19.88 v
Ucp2 Uncoupling protein 2 2.77 3.33 2.11 3.09 v
Vamp1 Vesicle associate
membrane protein 1
−1.02 4.69 2.85 4.96 v
Vmn1r7 Vomeronasal 1 receptor 7 2.08 2.58 2.01 2.51 v
Yif1a Yip1 interacting factor
homolog A (S. cerevisiae)
2.43 2.08 2.20 2.22 v
Zfp455 Zinc finger protein 455 3.18 3.78 2.31 2.13 v
Zfp784 Zinc finger protein 784 5.04 2.87 2.29 2.06 v
1110015O18Rik RIKEN cDNA
1110015O18 gene
2.45 3.46 7.34 8.67 v
(Continued)
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TABLE 1 | Continued
Gene Complete name fc_m355_
nu_cx
fc_m355_
nu_hp
fc_m511_
nu_cx
fc_m511_
nu_hp
NOT
in ABA
NEG
in ABA
POS
in ABA
POS
in LH
POS in
parvafox
1700047M11Rik RIKEN cDNA
1700047M11 gene
3.85 3.47 5.37 12.00 v
3110083C13Rik RIKEN cDNA
3110083C13 gene
2.03 2.23 3.26 3.58 v
5031410I06Rik RIKEN cDNA 5031410I06
gene
2.09 2.91 4.10 6.81 v
5830454E08Rik RIKEN cDNA
5830454E08 gene
2.26 2.90 −1.69 1.38 v
A230001M10Rik RIKEN cDNA
A230001M10 gene
2.23 3.38 2.11 3.48 v
B230323A14Rik RIKEN cDNA
B230323A14 gene
4.47 5.23 6.74 6.73 v
Gm10408 Predicted gene 10408 2.08 3.94 3.30 4.01 v
Gm10409 Predicted gene 10409 2.08 4.36 3.95 2.51 v
Gm13157 Predicted gene 13157 6.17 4.88 2.83 4.29 v
Gm19763 Predicted gene, 19763 5.09 6.28 2.25 2.09 v
Gm3500 Predicted gene 3500 2.01 2.66 2.45 2.55 v
Gm3515 Predicted gene 3515 3.59 7.15 11.80 15.33 v
Gm410 Predicted gene 410 2.22 2.61 2.91 2.73 v
Gm4988 Predicted gene 4988 2.13 2.67 2.07 2.90 v
AffyID:17296943 – 2.90 3.70 2.43 3.42 v
AffyID:17366828 – 2.78 3.72 4.15 3.37 v
AffyID:17370057 – 5.07 4.82 4.42 3.12 v
AffyID:17381937 – 4.19 5.35 3.59 9.54 v
AffyID:17398719 – 2.08 2.10 2.66 3.56 v
AffyID:17428186 – 3.12 3.51 3.81 3.91 v
AffyID:17460252 – 2.71 3.07 6.50 7.11 v
The enriched genes were selected on the basis of the fold-change values of each mouse represented in the 3rd to 6th column in the table (nu_cx, parvafox nucleus vs. cortex; nu_hp,
parvafox nucleus vs. hippocampus). The gene-specific expression levels are represented by the log2 of the fluorescence intensity that was measured on the GeneChip®. The following
possibilities were distinguished: absence from the ABA-database (NOT in ABA), negative results in the database (NEG in ABA), positive results in the database (POS in ABA), positive
results in the database for the lateral hypothalamus (POS in LH), positive results in the database for the region that is occupied by the parvafox nucleus (POS in parvafox). The genes
that are recognized for the first time to be enriched in the parvafox nucleus are indicated by a gray-shading of the background in the last column; those that were identified as being
expressed in the parvafox nucleus in an earlier study by Girard et al. (2011) are not highlighted. Agt and Itih3 were exclusively expressed in glia (not in neurons). According to the ABA-ISH
database, Npb and Foxb1 were not enriched in the hypothalamus, even though their expression in this region has been demonstrated by other authors, both immunohistochemically
and by in-situ hybridization (Dun et al., 2005; Civelli et al., 2006).
(Genes that were found over-expressed compared to both the cortex and the hippocampus are formatted in bold, the genes over-expressed relative to either the cortex or the
hippocampus and not both are in italic and underlined, and those that were found highly expressed in only one of the mice are in italic.)
were also studied, using the GO (Gene Ontology) bioinformatics
platform and the UniProtKB/Swiss-Prot database.
RESULTS
Gene-Expression Analysis of the Parvafox
Nucleus
Using Partek R© Genomics SuiteTM software, we first examined the
expression levels of the genes that are known to be enriched in
the parvafox nucleus, such as Slc17a6 and Pvalb, and of those
that have been demonstrated to remain unexpressed, such as
Slc17a7 and Gad1. This analysis confirmed the expression levels
of Slc17a6, the gene encoding the vesicular glutamate transporter
2 (Vglut2), to be higher in the parvafox nucleus than in either the
cortex or the hippocampus. Pvalb is expressed in both the cortex
and the hippocampus, but at a much higher level in the parvafox
nucleus. The expression levels of Slc17a7 (encoding Vglut1)
and Gad1 (coding for the GABA-synthesizing enzyme glutamate
decarboxylase 1) in the parvafox nucleus were low compared to
those in the cortex and the hippocampus (not shown).
A further analysis of the data was conducted using the
Bioconductor package limma in R. A gene was considered
to be enriched in the parvafox nucleus if its expression
levels in the mice were 2-fold higher than those in both the
hippocampus and the cortex. This was a very strict selection
criterion, and its investigation revealed the enrichment of 67
genes in the parvafox nucleus (Table 1). The ABA-ISH and
the B∗ database were screened for the specific expression of
each of these genes in the region occupied by the parvafox
nucleus. The function of these genes was ascertained by
a search of the UniProtKB/Swiss-Prot database. The genes
that were enriched in the parvafox nucleus (Table 1) can
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FIGURE 1 | Expression of the mRNA for the glycine-receptor subunits α-1, α-2 and α-3 in the parvafox nucleus as found in the ABA-ISH. (A,D,G) In situ
hybridization-images for Pvalb, downloaded from the ABA website, defining the location of the parvafox nucleus (surrounded by a red circle or rectangle). (B,E,H): The
mRNAs for the glycine-receptor subunits α-1, α-2, and α-3 are expressed within the confines of the parvafox nucleus. In (C,F,I) the expression level of Glra1, Glra2,
and Glra3 is visualized with pseudocolors. (A–F) are sagittal sections and (G–I) coronal sections. (Image credit: Allen Institute.) Scale bars represent 100 µm.
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FIGURE 2 | Immunohistochemical localization of the Glyrα2 receptor in the parvafox nucleus. In overview pictures, the Glyrα2 immunoreactive sites in the
hypothalamus are concentrated in the ventrolateral hypothalamus and the mammillary nuclei. At low magnification, a meshwork of Glyrα2 immunoreactive fibers (A) is
intermingled with Parv-immunoreactive neurons (B,C). At higher magnification, Glyrα2 immunoreactivity decorates the dendrites (arrows, D) and cell body of
Parv-positive neurons (E,F).
be classified as follows: neuropeptide activity (Adcyap1, Npb,
Nxph4, Pmch), receptors (Glra2, Gpr139, Vmn1r7), transporters
(Slc17a6), chloride channels (Ano4), enzymes (Agxt2l1, Dgkk,
Fam113b, Gpx3, Hyi, Phyhd1, Plcb4, Ucp2), peptide-hormone
precursors (Agt), transcription factors (Ddx5, Ebf3, Pitx2),
peptidase inhibitors (Itih3, Serpinb1b), apolipoprotein (Apoc1),
angiogenesis regulators (Baiap3), cytoskeleton growth regulator
(Capza1), nucleosome-interacting proteins (Hist1h1b, Hmgxb4),
cell recognition (Igsf1), cell-cell adhesion (Fndc3a,Mpp7), neural
development (Slitrk6), cell growth and differentiation (Sfrp5),
regulators of membrane traffic (Rhobtb3, Yif1a), unknown
functions (Lhfpl3, Lhfpl5, Mthfd2l, Rnf122, Trav9d-3, Zfp455,
Zfp784), non-coding RNA (Rmst, Rny1, Snord42b), and RNA-
processing (Scarna3a). Eight predicted genes, 6 RIKEN-cDNAs
and 7 non-characterized sequences were also enriched. We then
expanded the initial list with 15 potential genes (Cbln1, Drd2,
Ephb1, Foxb1, Glra1, Glra3, Kcnab3, Lgi2, Lhx1, Lrrc6, Ndufs1,
Npsr1, Penk, Vamp1, 5830454E08Rik), which initially failed the
selection criteria but appeared to be highly overexpressed in
either the hippocampus or the cortex, or in one of the mice
(Table 1), thus raising the total number of genes potentially
expressed in the parvafox nucleus to 82.
By checking the expression of these 82 gene profiles in
the ABA-ISH, their occurrence in the parvafox region of the
lateral hypothalamus was confirmed visually for 26 (Table 1,
last column), 10 of which were already known to occur in the
parvafox region (Girard et al., 2011). Submitting these genes
to an additional check with the B∗ databases (Supplementary
Table 1), this third criterion confirmed the enrichment of 13 of
them (Adcyap1, Agt, Cazpa1, Cbln1, Drd2, Fndc3a, Glra1, Glra2,
Glra3, Gpx3, Itih3, Nxph4, Slc17a6) in the parvafox nucleus. On
the basis of morphological criteria in the ABA-ISH, we suspected
that Agt and Itih3 were expressed by glia rather than by neurons.
Remarkably, both in the ABA-ISH and the B∗ database, the
results for neuropeptide b and Foxb1 were negative (Table 1,
Supplementary Table 1), despite they having been successfully
identified by in-situ hybridization in the hypothalamus by other
authors (Dun et al., 2005; Jackson et al., 2006; Schulz et al.,
2007). Consequently, in these specific cases we interpret the
ABA-ISH-database result as a false negative one.
For many of the other genes that were revealed by the
microarray analysis to be enriched in the parvafox nucleus,
corresponding confirmation in the ABA-ISH images or in the B∗
database were either negative or not possible. For example, in the
ABA-ISH the expression of 28 genes had not been performed
and 14 genes were negative. Alternatively, the localization was
either in the lateral hypothalamus at large (5 genes) or outside
it (9 genes). In ABA-ISH images of sagittal sections, the parvafox
nucleus was more difficult to identify with certainty, and the data
were consequently less unequivocal. The findings of the detailed
evaluation are summarized as a whole in the Table 1.
The most noteworthy result was the finding that the glycine-
receptors subunit alpha-2 (Glra2) was expressed at higher levels
in the parvafox nucleus than in both the cortex and the
hippocampus, with a mean fold-change of +4.53 (Table 1).
The glycine-receptor subunit alpha-3 (Glra3), although excluded
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TABLE 2 | A selection of 9 genes of particular interest because of their
novelty and possible roles as markers or as neuromodulators (for an
extended list of genes see Table 1) has been confirmed to be expressed in
the transcriptome of the parvafox nucleus by qRT-PCR.
Gene-array qRT PCR* B* ABA IC Literature
Cbln1 x x x x
Drd2 x x x x
Ephb1 x x x
Foxb1 x x neg x** x
Glra1 x x x x
Glra2 x x x x x
Glra3 x x x x
Npb x x neg x
Npsr1 x x No data x
We also examined the expression of these 9 genes in the BrainStars (B*) database and
the ABA-ISH database, additionally we performed immunohistochemistry (IC) to validate
the expression of Glra2 and Foxb1. Glra2 satisfies all five criteria for expression in the
parvafox nucleus and represents the most robust result of this study. Cerebellin (Cbln1)
and the dopamine 2 receptor (Drd2) meet four of the five criteria for occurrence in the
parvafox nucleus.
Foxb1 and Npb are positive in our own gene-array and have been revealed by others (Dun
et al., 2005; Civelli et al., 2006) to occur in the lateral hypothalamus, respectively in the
parvafox nucleus (Bilella et al., 2014) but could not be confirmed neither in the ABA-ISH
nor in the B* databases.
*p values calculated in Student’s t-test (∆Ct of both nuclei vs. both cortex and
hippocampus).
**Positive in Foxb1-Cre-Egfp knock-in mice (Bilella et al., 2014).
by our strict selection criteria, was also expressed at high
levels in the parvafox nucleus, with a mean fold-change of
+11.92 in mouse 511 (Table 1 and Figure 1B). Screening of the
B∗-microarray database revealed the glycine-receptor subunit
alpha-1 (Glra1) to be likewise expressed at higher levels in
the parvafox region (FC = 3.5) than in the hippocampus
(see Supplementary Table 1). The expression of these three
alpha-subunit isoforms of glycine receptors in the parvafox
nucleus was confirmed by visual screening of the ABA-
ISH database (Table 1, Figure 1) and for Glyrα2 additionally
also by immunofluorescence staining with specific antibodies
(Figure 2).
Quantitative Real-Time PCR
Nine genes of particular interest because of their role as markers
or neuromodulators (for the extended list of genes see Table 1)
were selected to verify the results of the gene microarray study
and to confirm their expression in the region of the parvafox
nucleus by quantitative real-time PCR (Table 2). We calculated
the expression values based on the 2−11CT method as described
in the paper of Livak and Schmittgen (2001). The log2FC values
obtained by the qRT-PCR assay are listed in Table 3. Student’s
t-tests were performed to assess statistical significance. We were
able to confirm the enrichment of 9 genes in the parvafox nucleus:
Cbln1, Drd2, Ephb1, Foxb1, Glra1, Glra2, Glra3, Npb and Npsr1.
P-values calculated to compare the 1CT values of the parvafox
nucleus to the cortex and hippocampus of both mice showed
that the enrichment was significant for all nine genes: Cbln1
(p = 0.0054) Drd2 (p = 0.003), Ephb1 (p = 0.00009), Foxb1
(p = 0.0008), Glra1 (p = 0.013), Glra2 (p = 0.000001), Glra3 (p
= 0.003), Npb (p = 0.00073) and Npsr1 (p = 0.007) (Table 3).
These results coincide with the microarray fold change values;
however, in some cases the expression levels were considerably
higher whenmeasured by qRT-PCR (see Supplementary Table 2).
Analysis of the Putative Roles of the Genes
That Were Enriched in the Parvafox
Nucleus
We conducted a MetaCore (GeneGO)-enrichment analysis on a
set of genes that had been revealed to be expressed in the parvafox
nucleus by the combined results of the gene-microarray, the
ABA-ISH database and the B∗-database evaluations, as well
as previous observations (Girard et al., 2011) (Table 4). This
analysis revealed high expression levels of specific genes encoding
proteins of various biological processes, the most noteworthy
being synaptic transmission (Ionotropic glutamate receptor,
Kv1.2, GluR5, Galpha(i)-specific amine GPCRs, GlyRA3,
Galpha(q)-specific peptide GPCRs, HCN, KCNAB3, Cerebellin
1, NEFL, Kainate receptor, HCN2, VAMP1, Kv3.1, GlyRA1, PLC-
beta), neuropeptide signaling pathway (Galpha(s)-specific CRF
GPCRs, PACAP, GlyRA2, Neurexophilin 4, Galpha(q)-specific
peptide GPCRs, Neuropeptide S receptor, CRHR1, Enkephalin
A, GlyRA1), and regulation of the inhibitory postsynaptic
membrane potential (Ionotropic glutamate receptor, GluR5,
Galpha(i)-specific amine GPCRs, Kainate receptor, GlyRA1).
A relation to behavioral response to pain was also manifested
(Ionotropic glutamate receptor, Galpha(s)-specific CRF, GPCRs,
GluR5, Galpha(q)-specific peptide GPCRs, CRHR1, Kainate
receptor) (Table 4).
Immunohistochemistry Revealed
Parv-Positive Neurons of the Parvafox
Nucleus to Express Glycine Receptor α2
For an additional independent verification of themost robust and
interesting results, an antiserum against the Glyrα2-receptor was
used to detect immunoreactivity in the hypothalamus. Positive
immunolabeling was selectively observed in a few hypothalamic
regions, one being the parvafox nucleus (Figures 2A–C). At
higher magnification, the immunoreactivity was revealed to
be associated with the plasma membrane of the Parv-positive
neurons in this region (Figures 2D–F). Immunoblot analysis
of murine hypothalamus protein extract with the antiserum
against Glyrα2 resulted in a sharp band below 50 KDa, the
expected molecular weight for the Glyrα2 receptor (Figure 3),
confirming the presence of Glyrα2 in the hypothalamus,
as well as the specificity of the Glyrα2-antibody used in
our study. In addition to the hypothalamus, we detected
Glyrα2 in hippocampal and cortical lysates (Figure 3) as well,
regions that served as reference structures in the microarray
analysis.
GlyT2-EGFP-Positive Axon Terminals End
on Parv-Neurons of the Parvafox Nucleus
To confirm that Parv-neurons of the parvafox-nucleus indeed
receive input from glycinergic nerve cells, Glycine transporter 2
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TABLE 3 | Expression values presented as fold change on log2 scale obtained by qRT-PCR.
Cbln1 Drd2 Ephb1 Foxb1 Glra1 Glra2 Glra3 Npb Npsr1
log2FC NU vs. CX
AVG 4.03 1.89 4.21 1.96 3.07 1.23 2.29 4.62 1.67
SEM 0.86 0.54 0.57 0.25 2.30 0.32 0.45 0.45 0.62
p value 0.010618 0.034325 0.00611501 0.150336 0.156518 0.001574208 0.000616 0.003475 0.014121
log2FC NU vs. HP
AVG 4.79 4.63 4.47 6.69 6.64 2.23 9.33 11.37 3.79
SEM 2.72 0.71 0.59 0.93 1.20 0.15 0.98 1.70 0.97
p value 0.034305 0.00072 1.0328E-05 2.47E-06 0.000141 4.03646E-13 4.79E-06 0.000126 0.003092
log2FC NU vs. CX + HP
AVG 4.80 1.53 3.86 4.62 1.50 1.30 2.57 6.76 0.92
p value 0.005454 0.003403 9.0766E-05 0.000799 0.012946 6.00367E-07 0.003527 0.000728 0.007576
Expression values were calculated based on the 2−∆∆CT method and then averaged. ∆CT values of the parvafox nucleus were contrasted to ∆CT values of the cortex, respectively to
the ∆CT values of the hippocampus; additionally, expression values were also calculated based on the ∆CT values of the nucleus versus cortex AND hippocampus. When compared to
the cortex, or to the hippocampus, the majority of the genes were significantly over-expressed in the parvafox nucleus, with exception of Foxb1 and Glra1 (compared to cortex). When
compared to the cortex AND hippocampus, all the genes were significantly over-expressed in the parvafox nucleus. Error bars show SEM. (*p< 0.05, **p < 0.005, ***p < 0.0005).
(GlyT2)-expression was studied in GlyT2-EGFP mice (Zeilhofer
et al., 2005). Double-immunolabeling of Parv and GFP
revealed a dense net of GlyT2-EGFP positive axons and
axon terminals in the parvafox region. We found that several
GlyT2-EGFP axon terminals indeed ended on Parv-neurons
(Figures 4A–C). Confocal laser microscope z-stacks were then
subjected to 3D-reconstruction with the Imaris software for
a better visualization (Figure 4D). The 3D-reconstruction
demonstrated GlyT2-EGFP axon terminals in apposition both
to the dendrites (Figure 4E, see arrows) and to the perikarya
(Figure 4F, see arrows) of Parv-neurons of the parvafox
nucleus.
DISCUSSION
Laser-capture microdissection has been used in a variety of
publications for the identification of marker genes that may help
in the genetic dissection of functionally well characterized regions
of the medial hypothalamus (Segal et al., 2005; Paulsen et al.,
2009; Landmann et al., 2012; Lee et al., 2012; Humerick et al.,
2013).
The aim of our gene-microarray analysis was primarily
the search for neuromodulator genes in neurons of an ill-
defined lateral hypothalamic region of as yet unknown function.
Notwithstanding the methodological complexity, the expression
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TABLE 4 | A GeneGO (MetaCore) enrichment analysis was performed on 45 genes found enriched in our microarray, in the ABA-ISH and in the B*
database, supplemented with genes which had previously been found to be positive in the parvafox nucleus (Girard et al., 2011).
Rank GO Processes Total P value Min FDR In Data Network objects
1 Synaptic transmission 826 3.628E-14 3.813E-11 17 KCNAB3, Ionotropic glutamate receptor, NEFL, Cerebellin 1, Kainate
receptor, Kv1.2, GluR5, HCN2, VAMP1, Kv3.1, Galpha(i)-specific amine
GPCRs, GLyRA3, GlyRA1, Galpha(q)-specific peptide GPCRs,
PLC-beta, HCN
2 Neuropeptide signaling pathway 138 2.343E-12 1.231E-09 10 Galpha(s)-specific CRF GPCRs, PACAP, Enkephalin A, GlyRA2,
Neurexophilin 4, GlyRA1, Galpha(q)-specific peptide GPCRs,
Neuropeptide S receptor, CRHR1
3 Regulation of inhibitory
postsynaptic membrane
potential
24 2.331E-11 8.165E-09 6 Ionotropic glutamate receptor, Kainate receptor, GluR5,
Galpha(i)-specific amine GPCRs, GlyRA1
4 Regulation of membrane
potential
413 8.292E-11 2.179E-08 8 Ionotropic glutamate receptor, Kainate receptor, GluR5, HCN2, GlyRA1,
Galpha(q)-specific peptide GPCRs, HCN
5 Behavioral response to pain 30 1.352E-10 2.842E-08 6 Ionotropic glutamate receptor, Kainate receptor, Galpha(s)-specific CRF
GPCRs, GluR5, Galpha(q)-specific peptide GPCRs, CRHR1
6 Negative regulation of
voltage-gated calcium channel
activity
6 6.228E-10 1.091E-07 4 Galpha(s)-specific CRF GPCRs, Dopamine D2 receptor,
Galpha(i)-specific amine GPCRs, CRHR1
7 Negative regulation of synaptic
transmission, glutamatergic
19 1.140E-09 1.712E-07 5 Ionotropic glutamate receptor, Kainate receptor, GluR5, Dopamine D2
receptor, Galpha(i)-specific amine GPCRs
8 Startle response 41 4.127E-09 5.422E-07 5 Enkephalin A, Dopamine D2 receptor, Galpha(i)-specific amine GPCRs,
GlyRA1
9 Regulation of JNK cascade 178 7.792E-09 9.099E-07 5 Ionotropic glutamate receptor, Kainate receptor, Ephrin-B receptors,
Galpha(q)-specific peptide GPCRs, Ephrin-B receptor 1
10 Ion transport 1408 1.008E-08 1.059E-06 14 KCNAB3, Ionotropic glutamate receptor, Kainate receptor, Kv1.2,
GluR5, GlyRA2, HCN2, SLC17A6, SCN4B, Kv3.1, GlyRA3, GlyRA1,
HCN
The distribution in GeneGO Processes revealed enrichment in pathways and processes involved in subcellular mechanisms (neurotransmission, ion transport, neuropeptide signaling),
as well as in the startle response and the behavioral response to pain.
FIGURE 3 | Detection of Glyrα2 on hypothalamic, hippocampal and
cortical extracts by immunoblot. The antiserum against Glyrα2 detects a
single band below 50 KDa (arrow) in an immunoblot of hypothalamic,
hippocampal and cerebral cortical extracts submitted to SDS-gel
electrophoresis. (HY, hypothalamus; HP, hippocampus; CX, cortex).
of the receptors for the inhibitory neurotransmitter glycine in the
parvafox nucleus is now well documented by our study.
This study has permitted an extension of the list of genes
that are preferentially expressed in the parvafox nucleus of the
ventrolateral hypothalamus. In addition to the 76 genes that were
previously identified to be expressed by Girard et al. (2011),
additional 82 (some overlapping) have been shown to be enriched
in this region by our gene-microarray analysis. A survey of the
ABA-ISH and B∗ databases for their hypothalamic distribution
confirmed the expression of at least 13 of these genes in the
parvafox nucleus. The expression of nine particularly relevant
genes involved in neuromodulation was corroborated by qRT-
PCR.
Interestingly, only a few genes (Adcyap1, Pitx2, Slc17A6,
Plb4, Itih3, Hist1h1b, Tmem163) were revealed to be commonly
expressed by the gene-microarray analysis and the ABA-ISH-
database screening (Girard et al., 2011) thereby indicating
that the two methodologies differ in sensitivity, specificity and
selectivity. Although, both the in-situ-hybridization technique
and the gene-microarray approach revealed an expression
of various gene-families (e.g., neurotransmitters, transcription
factors, extracellular molecules), the individual members thereof
that were revealed by the ABA-ISH-database screening differed
from those that were brought to light by the gene-microarray
analysis.
The most obvious explanation of this discrepancy is that
the gene-array search for the relative abundances based on a
comparison between regions, namely, between the hypothalamus
and either the cortex or the hippocampus. Consequently,
the genes that are expressed in both regions were excluded.
For example, the potassium channels (Kcna1, Kcna2, Kcnab2,
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FIGURE 4 | Localization of GlyT2-EGFP-positive axons and axon terminals in the parvafox nucleus. Confocal laser micrographs of
double-immunohistochemistry for GFP (green, A) and Parv (red, B) performed on brain sections of transgenic GlyT2-EGFP mice revealed the presence of several
axons and axon terminals in the hypothalamic region encompassing the parvafox nucleus. The merged image (C) shows GlyT2-EGFP-positive terminals around the
perikaryon and the dendrites of a Parv-positive neuron. Three-dimensional reconstruction by Imaris (D) reveals several EGFP-positive terminals on the dendrite (E, see
arrows), as well as on the cell body (F, see arrows) of the Parv-neuron.
Kcnab3, Kcnc1, Kcnc2, and Kcnk1), which are responsible for the
high firing rates of Parv-positive neurons in the cortex and the
hippocampus, were recognized as being expressed in the parvafox
nucleus by the ABA-ISH-database screening (Girard et al., 2011)
but not by the gene-microarray analysis (Table 1). Nevertheless,
a detailed comparison of the long list of expressed genes in
the gene-microarrays of both mice revealed that approximately
40% of those that were registered in the study of (Girard et al.,
2011) were also enriched in the gene-microarray of the parvafox
nucleus (results not shown).
For some genes, no in-situ-hybridization data exist as yet in
the ABA-ISH (Table 1). For others (e.g., Npb, Foxb1), screening
of the ABA-ISH database yielded negative results, even though
the expression of such genes in the hypothalamus has been
demonstrated by in-situ hybridization or immunohistochemistry
in other reports (Dun et al., 2005; Civelli et al., 2006). Low-
level transcripts may be below the threshold of detection by in
situ hybridization techniques, andmore sensitive techniques such
as qRT-PCR may be needed to validate their expression in the
parvafox nucleus. Hence, falsely negative results partially account
for the discrepant findings.
On the other hand, it is also conceivable that the gene-
array technique yields falsely-positive or falsely-negative results
(Mitchell and Mirnics, 2012). The former may arise from the
non-specific binding of cDNAs to homologous oligonucleotide
probes, and the latter from the privileged amplification of certain
mRNAs at the expense of others.
Hence, taking into account the combined results of the three
approaches (Gene-array/ABA/B∗) maximizes the reliability
of the information we have gained. The counterchecking of
findings revealed by a gene-microarray analysis against those
disclosed by in-situ hybridization (screening of the ABA-ISH
database) and in the B∗ database, is a legitimate mean of
predicting the expression profiles of the neurons in the parvafox
nucleus. Albeit so, it represents only a first approximation:
the definitive allocation of gene-expression activity to a
specific sub-population of neurons awaits the instigation of
antibodies against the corresponding proteins for a definitive
immunohistological confirmation of their localization to
specific sub-population of neurons (Parv- or Foxb1-expressing).
Furthermore, functional in-vitro studies investigating for
example the effects of blocking glycinergic transmission or
applying locally the corresponding neurotransmitter will be
needed to confirm the physiological roles of the genes of
interest.
The glycinergic inhibitory system is particularly powerful
in the spinal cord and the brainstem, where virtually all
immunoreactive cell-bodies are located (Kirsch, 2006). However,
glycine-immunoreactive fibers and terminals have been observed
in various parts of the brain by different authors (Zeilhofer
et al., 2005; Barreiro-Iglesias et al., 2013) and glycine-induced
chloride-currents were discovered already in 1989 in dissociated
hypothalamic neurons (Akaike and Kaneda, 1989). Functional
glycine receptors have been detected in higher brain centers,
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such as the hippocampus (Brackmann et al., 2004; Keck and
White, 2009; Xu and Gong, 2010), and the glycine transporter
2 has been demonstrated in the whole brain as well as in the
hypothalamus (Zeilhofer et al., 2005). The glycine receptor alpha
2 subunit alone can build functional receptors in adults and
is particularly expressed in hippocampus and cortex (Meier
et al., 2014). The expression of other components of the
glycinergic system (glycine itself, glycine transporters, Glyrα1
and Glyrα3 glycine receptors, gephyrin) in the parvafox nucleus
has been confirmed partly by the ABA-ISH-database screening
(Figure 1) and by ongoing immunohistochemical studies. Hence,
glycine appears to be an important inhibitory neurotransmitter
in the parvafox nucleus, as also underlined by the Gene-
GO enrichment analysis. The cell bodies giving rise to the
axonal endings that abut on the neurons of the parvafox
nucleus may be located in the brainstem, where aggregates
of glycinergic neurons have been described (Zeilhofer et al.,
2005).
In conclusion, the use of the laser capture microdissection
and gene-microarray-based approach in combination with data
verification in the ABA-ISH and B∗ databases has proved to be on
efficient means of gaining further insight into the transcriptome
of the murine parvafox nucleus. Nine genes were confirmed by
independent techniques to be enriched therein. Some of these
markers may be useful to define subpopulations of parvafox
neurons as a prelude to studying their circuitry and function.
The augmented expression levels of several of these genes shed
light on the functional mechanisms that may be operative in the
parvafox nucleus, for example, the glycine-mediated inhibitory
control.
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